Read on Twitter
Sure.
Early in the COVID-19 pandemic, hydroxychloroquine quickly came to be widely used on the basis of very thin evidence—a very small randomized trial (1) and a poorly done small observational study (2), both originally posted on a preprint server rather than published in the https://twitter.com/eraofw/status/1287914277416779777
Early in the COVID-19 pandemic, hydroxychloroquine quickly came to be widely used on the basis of very thin evidence—a very small randomized trial (1) and a poorly done small observational study (2), both originally posted on a preprint server rather than published in the https://twitter.com/eraofw/status/1287914277416779777
peer-reviewed literature. In early May 2020, two large observational cohort studies that found no association between administration of hydroxychloroquine and the rate of death or respiratory failure in hospitalized patients with COVID-19.
Press releases have reported negative
Press releases have reported negative
results from 2 large randomized clinical trials sponsored by the National Institutes of Health and the U.K. National Health Service.RECOVERY consortium.
A randomized clinical trial of hydroxychloroquine as postexposure prophylaxis failed to show any benefit in preventing
A randomized clinical trial of hydroxychloroquine as postexposure prophylaxis failed to show any benefit in preventing
progressing to disease, and a second randomized trial in patients with mild to moderate disease also failed to demonstrate faster conversion to negative viral status in hydroxychloroquine-treated patients.
In a recent study, investigators sought to evaluate the utility of
In a recent study, investigators sought to evaluate the utility of
hydroxychloroquine in patients with very mild illness. This created significant operational hurdles related to conducting a trial at a time when in-person visits were difficult if not impossible and testing shortages made confirmation of a COVID-19 diagnosis quite difficult in
patients with very mild illness. The study has clear limitations related to these issues. Although 82% of patients had laboratory-confirmed COVID-19 or documentation of close contact with a confirmed case, only 58% of study participants themselves received COVID-19 testing. The
primary outcome, which was changed during the study with the permission of the data and safety monitoring board, relied on a novel and not previously validated tool for symptom assessment.
The investigators found no clinically or statistically significant difference in change
The investigators found no clinically or statistically significant difference in change
in symptom severity over 14 days in persons who received hydroxychloroquine compared with those who did not. Medication side effects, although minor, were more common in the hydroxychloroquine-treated group. As expected in a relatively young population with mild illness and
little comorbid illness, hospitalizations were uncommon overall and did not differ statistically between the 2 groups.
Taken together with other published randomized clinical trials, this recent study provides strong evidence that hydroxychloroquine offers no benefit in
Taken together with other published randomized clinical trials, this recent study provides strong evidence that hydroxychloroquine offers no benefit in
patients with mild illness. http://Annals.org 7/16/20.
So, currently there is little to support the use of hydroxychloroquine for COVID, and I personally am unaware of any reputable experts in this area that are currently using this medication.
So, currently there is little to support the use of hydroxychloroquine for COVID, and I personally am unaware of any reputable experts in this area that are currently using this medication.
